uniQure N.V. $QURE Stock Acquired by Pekin Hardy Strauss Inc.

Pekin Hardy Strauss Inc. lifted its position in uniQure N.V. (NASDAQ:QURE) by 63.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 153,890 shares of the biotechnology company’s stock after buying an additional 59,640 shares during the period. Pekin Hardy Strauss Inc.’s holdings in uniQure were worth $3,718,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in QURE. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of uniQure during the third quarter valued at approximately $86,000. China Universal Asset Management Co. Ltd. bought a new position in uniQure in the 3rd quarter valued at approximately $310,000. Maxi Investments CY Ltd bought a new position in uniQure in the 3rd quarter valued at approximately $966,000. IFP Advisors Inc lifted its position in uniQure by 18.0% in the 3rd quarter. IFP Advisors Inc now owns 3,280 shares of the biotechnology company’s stock valued at $79,000 after acquiring an additional 500 shares in the last quarter. Finally, Activest Wealth Management purchased a new stake in uniQure during the 3rd quarter valued at $121,000. Institutional investors own 78.83% of the company’s stock.

Analysts Set New Price Targets

QURE has been the subject of a number of research analyst reports. HC Wainwright reissued a “buy” rating on shares of uniQure in a report on Tuesday, September 29th. Wells Fargo & Company reaffirmed an “overweight” rating and set a $75.00 price target on shares of uniQure in a report on Tuesday, September 29th. William Blair raised uniQure to a “strong-buy” rating in a report on Wednesday, September 23rd. Stifel Nicolaus set a $71.00 price objective on uniQure in a research report on Wednesday. Finally, Wall Street Zen lowered uniQure from a “hold” rating to a “sell” rating in a research report on Saturday, September 5th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $56.83.

uniQure Trading Down 8.8%

Shares of QURE stock opened at $21.01 on Friday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 10.01 and a current ratio of 11.52. uniQure N.V. has a 12-month low of $8.73 and a 12-month high of $51.72. The firm’s 50 day moving average is $32.42 and its 200 day moving average is $29.68.

uniQure (NASDAQ:QURE) last announced its earnings results on Wednesday, November 4th. The biotechnology company reported ($0.88) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.04. The business had revenue of $5.20 million during the quarter, compared to analyst estimates of $6.17 million. uniQure had a negative net margin of 1,154.84% and a negative return on equity of 96.34%. On average, equities analysts expect that uniQure N.V. will post -3.82 earnings per share for the current fiscal year.

Trending Headlines about uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: The FDA granted priority review to uniQure’s BLA for AMT-130, with a target decision date of May 1, 2027. Acceptance and an expedited review provide a defined regulatory milestone for the company’s lead program. uniQure Q3 2026 results and company update
• Neutral Sentiment: Q3 loss narrowed year over year to $0.88 per share. That result beat some published consensus figures but missed another estimate; revenue of $5.2 million was below analyst expectations, leaving the quarter’s financial read-through mixed. UniQure Q3 loss narrows, revenue increases
• Negative Sentiment: The FDA review also puts the path beyond the application in focus: uniQure has outlined a confirmatory study of about 200 patients. The added study and its execution could mean further cost, time and clinical risk, tempering optimism around the 2027 decision date. AMT-130 confirmatory study and PDUFA date

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on developing gene therapies for serious and life-threatening diseases. The company uses adeno-associated virus (AAV) vectors and other genetic medicine technologies to deliver therapeutic genes intended to address the underlying causes of disease.

uniQure’s best-known product is HEMGENIX, a gene therapy for adults with hemophilia B caused by factor IX deficiency. HEMGENIX was developed by uniQure and is commercialized by CSL Behring under a global licensing agreement.